Recent guidelines recommend glucagon-like peptide 1 receptor agonists early in the disease course for high-risk patients, but only 0.5% of patients in our study with type 2 diabetes were using this therapy [10]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.